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Clonal hematopoiesis (CH) is a phenomenon in which
somatic mutations originating from hematopoietic pro-
genitors are detected in peripheral blood cells1,2. The
prevalence of CH increases with age, and CH can be
detected in 10–25% of healthy, elderly individuals1–4. Very
sensitive methods may allow somatic mutation detection
in blood cells in 95% of 50–60-year olds5.
CH confers risk for myeloid malignancy and death1,2. In
addition, recent data has suggested that CH is also a risk
factor for cardiovascular disease1,6,7. In mice, Tet2 loss-of-
function in myeloid cells alone promoted atherosclerosis
and proinflammatory cytokine production6. Proin-
flammatory and dysregulated immune responses play
roles in the pathogenesis of multiple diseases. As an
example, rheumatoid arthritis (RA) is a chronic auto-
immune disease which leads to joint destruction. Despite
improved disease outcomes with modern treatments, RA
patients have increased risk for death and cardiovascular
disease. CH has not been studied in the context of RA
previously, except for one study containing self-reported
disease history of arthritis3.
Aplastic anemia (AA) and hypoplastic myelodysplastic
syndrome (hMDS) are characterized by hypocellular bone
marrow and peripheral-blood cytopenias, and are difficult
to distinguish8. Although T cells cause hematopoietic
stem cell destruction in AA, cytogenetic abnormalities
occur in 4–11%, and CH occurs in up to 50% of AA
cases8. AA confers a substantial risk for hematological
malignancy8.
In this project, we aimed to characterize CH in patients
with RA. Results were also compared with the data from
patients with AA and hMDS, immune-mediated diseases
which have established links with CH. In addition, we
hypothesized that CH may modulate chronic inflamma-
tion or disease activity in RA. Thus, we compared muta-
tion findings with clinical parameters to investigate
associations between CH and the clinical phenotype in
RA.
We collected peripheral blood samples from 59 RA
patients who fulfilled the ACR2010 classification criteria
for RA and had been monitored in the Helsinki University
Hospital rheumatology outpatient clinic after RA diag-
nosis. Twelve acquired AA and hMDS patients were
recruited from the Helsinki University Hospital hema-
tology clinic. We also used samples from two young
healthy controls (aged 18–22) as negative controls. All
patients gave written informed consent. The ethical board
of our institution approved the study and the declaration
of Helsinki principles were followed. Due to descriptive
nature of our study, no power calculations were
performed.
To detect CH, we designed a custom sequencing panel
based on Illumina’s TruSeq Custom Amplicon technology
(Illumina, San Diego, CA, USA). The panel was designed
as 250 base-pair amplicons with Illumine Design Studio,
and it comprised of 583 amplicons. The panel covered not
only genes that are commonly mutated in CH in healthy
individuals but also typically in AA patients. Coding exons
of 34 tumor suppressor genes and/or mutational hotspots
were sequenced (Supplementary table 1; exact genomic
coordinates provided as Supplementary Data). Sequen-
cing was performed with the Illumina HiSeq2500 system
with 150 paired-end reads, and the average coverage for
each amplicon is shown in the Supplementary figure 1.
Peripheral-blood DNA (250 ng) was used for sequencing,
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but for AA/hMDS patients, bone-marrow mononuclear
cells (MNC) were used, except for one patient (MDS1,
sample type was peripheral blood).
Sequencing data was analyzed by previously described
methods9. Briefly, sequencing reads were aligned to the
Hg19 genome with Bowtie2 and GATK IndelRealigner,
but bases with Phred score < 20 were excluded from
further analyses. Variants were required to have
sequencing depth > 500, variant base count > 20, and
comprise over 80% of all variant bases in the position.
Mismapped variants and variants within 5 base-pairs of
a 5 base-pair homopolymer were also discarded. Variant
with a variant-allele frequency > 35%, population var-
iants with a population frequency of over 1%, and var-
iants that occurred in more than ten individuals were
discarded as germline variants. The variants were
annotated with the Ensembl Variant Effect Predictor.
The Supplementary Material contains more detailed
information on variant calling and filtering.
Normal distribution of the data was investigated gra-
phically and with the Shapiro–Wilk test. Statistical tests
include two-sided Mann–Whitney test and Fisher’s exact
test for comparisons between groups. P-values < 0.05 were
considered statistically significant. Longitudinal data was
analyzed as In-transformed data with a linear mixed model
in SPSS using the unstructured covariance type. Sidak
correction was used for paired multiple comparisons in the
following analyses. Statistical analyses were performed
with Graphpad Prism 6 (Graphpad Software, La Jolla, CA,
USA) and SPSS Statistics v.23 (IBM, Armonk, NY, USA).
We discovered CH at 17% prevalence in RA and at 33%
in AA/hMDS, which are consistent with previous
reports1–4,8. The identified mutations fulfilled the criteria
for clonal hematopoiesis of indeterminate potential
(CHIP)10. All synonymous and non-coding mutations
were discarded along with mutations with < 2% variant
allele frequency (VAF), because we defined CH as a pro-
cess in which mutations provide survival advantage to
cells11. The 2% VAF cutoff has also been suggested
to define CHIP10. We did not require missense mutations
to occur in cancer gene databases or have deleterious
prediction scores by in silico tools, because these strate-
gies will cause underreporting of novel variants and over-
reporting of known variants.
In RA patients, DNMT3A mutations were the most
common, TET2 mutations ranking second (Figure 1a;
Table 1 and Supplementary table 2), consistently with the
mutational spectrum found previously in healthy con-
trols1,3,4. None of the DNMT3A mutations occurred in
the R882 AML/MDS hotspot that has previously been
described in CH1,2,7. Frameshift and nonsense mutations
comprised 8/12 of all mutations in RA patients (Fig. 1b),
and these disruptive mutations had higher VAFs than
missense mutations (Fig. 1c; p= 0.0191). This finding
suggests that these mutations give survival advantage to
the affected clones.
AA/hMDS patients (Supplementary tables 3–4) were
characterized by mutations in genes such as LAMB4, PIGA,
and STAG2, which differentiates them from RA patients
(Fig. 1a) and healthy controls8. Consistently with RA
patients, most AA patients harbored only one CH mutation
per patient, but one AA patient harbored two CH muta-
tions (Fig. 1d). Follow-up samples were available from two
AA/hMDS patients (AA1 and AA3). One of these patients
(AA1) harbored a LAMB4 mutation that occurred in one
follow-up sample but disappeared after anti-thymocyte
globulin treatment (Supplementary figure 2).
Extremely low VAFs are challenging to detect even with
modern sequencing methods. High sequencing coverage is
not the only solution to achieve sensitive mutation detec-
tion, because sequencing library preparation can induce
mutational artifacts, especially C>A transversions, to the
library DNA12. With a VAF cutoff at 2%, half of the single-
nucleotide changes were C>T mutations (Fig. 1e) in our RA
data, supporting the accuracy of mutation calling1–3,11.
The prevalence of CH increased with age in RA patients:
the overall prevalence of CH was 17% but in 70–79-year
olds it increased up to 25% (Fig. 1f). However, patients
with CH were not significantly older at sampling (Fig. 1g).
Nearly all studied RA patients were treated with anti-
rheumatic drugs before sample collection. The patients’
treatment histories included methotrexate in 98%,
hydroxychloroquine in 75%, sulfasalazine in 58%, leflu-
nomide in 10%, and biological drugs in 8.5% of cases. No
differences in the treatment histories were observed
between patients with or without CH (Table 1). Taken
together, the signature of CH in RA reflects the ageing
hematopoietic system with C>T transitions and mutations
in epigenetic regulators11.
As chronic inflammation may cause mutagenesis via
DNA damage13, we also aimed to explore if CH is linked
with disease severity. In our cohort (n= 59) we could not
detect any differences in clinical parameters (such as
smoking status, serostatus, disease activity at diagnosis or
other autoimmune disease) between RA patients with/
without CH (Supplementary figures 3–4; Supplementary
tables 5–6). Similarly, during four years of follow-up, no
differences emerged in blood cell indices between RA
patients with/without CH (neutrophil counts and mean
corpuscular volume (MCV) are shown in Fig. 1h, i; Sup-
plementary figure 4; Supplementary tables 7–10). This is in
line with previous findings in healthy controls, as CH does
not associate with cytopenias in hematologically unselected
patients1. However, it should be noted that our dataset may
lack statistical power to discover subtle changes.
CH mutations occur mostly in myeloid cells, but
mutations in lymphoid cells may also modulate auto-
immune responses. We recently discovered CD8+ T cells
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Fig. 1 DNMT3A and TET2 mutations are the most common mutations in rheumatoid arthritis patients. a The prevalence of patients with mutations in
different genes. b The percentages of frameshift, nonsense, missense, and splice site mutations identified in RA and AA/hMDS patients. c Truncating
mutations have higher VAFs than missense mutations (Mann–Whitney test P= 0.0191). d The overall prevalence (reported as percentage) of CH in RA
and AA/hMDS are shown, and the proportions of patients with one or multiple mutations are shown in color. e The percentage of different single-
nucleotide base changes of all single-base changes. f The cumulative prevalence of CH (as percentage) in RA patients. The bars show the percentage
of patients with CH in different age groups. The absolute numbers of patients with CH and the number of patients in each age group are also shown
in the figure. g The median ages of RA patients with/without CH did not show statistically significant difference (Mann–Whitney test P= 0.31). h The
neutrophil counts of RA patients seem to decrease during follow-up, but there was no difference between patients with/without CH. i The mean
corpuscular volume (MCV) increases during follow-up in RA patients, but there was no difference between patient with/without CH. The analysis was
performed using a linear mixed model and the P-values are based on post-hoc tests (Sidak correction) on time as a main effect. CH, clonal
hematopoiesis; VAF, variant allele frequency; fs, frameshift
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harboring somatic mutations in immune-related genes in
RA patients14. Similarly, AA- and Felty’s syndrome (RA
with neutropenia and splenomegaly) patients’ CD8+
T cells harbor somatic mutations9,15. Future research is
needed to address the “chicken or the egg” dilemma: does
autoimmunity increase mutation formation or do muta-
tions promote inflammation and autoimmunity?
Taken together, CH with a typical mutation profile occurs
in RA, but despite of years long systemic inflammation, the
rate of CH is not markedly increased. To our knowledge, this
is the first report describing the occurrence of CH in RA;
one previous study included patients with self-reported dis-
ease history but did not find a significant association with
self-reported arthritis and CH3. However, this data is pre-
liminary, and conclusive results would require analysis of a
larger cohort of patients. In addition, although no associa-
tions existed between CH and clinical severity of RA in our
data, future studies should assess if a specific mutation or a
subset of mutations could impact autoimmunity or treat-
ment responses. This is plausible, as CH shapes immune
responses in other disease contexts: it increases the risk for
cardiovascular endpoints1,7, and Tet2 deficiency in myeloid
cells promotes atherosclerosis and proinflammatory cytokine
production in mice6. Thus, understanding the functional
consequences of all CH-associated mutations, and their roles
in various disease conditions, is warranted in the future.
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